Janssen Pharmaceuticals, Gilead Sciences, Emcure Pharmaceuticals, and Mylan are key players in the Lenacapavir Injection Market.
1 report, 1 independent
Updated Jul 30
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Janssen Pharmaceuticals, Gilead Sciences, Emcure Pharmaceuticals, and Mylan are key players in the Lenacapavir Injection Market.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- South Africa rolled out the new injectable HIV/AIDS prevention drug, Lenacapavir, with the Health Minister announcing the distribution details.Sub-event
Four companies are key players in the Lenacapavir Injection Market.1 source
Keep exploring
The entities involved
-
Janssen Pharmaceuticals
business enterprise in United States of America
Nothing else this week.
-
Gilead Sciences
American company
- Required regulatory filings regarding institutional holdings were made by Gilead Sciences, Inc. with the Securities and Exchange Commission on June 11, 2026.
- A pilot program is underway involving the federal government, Benue State, and Gilead Sciences, with the state participating in the drug supply management.
-
Emcure Pharmaceuticals
Indian multinational pharmaceutical company
Nothing else this week.
-
Mylan
former pharmaceutical company
Coverage
Newest first; wire copies grouped- GlobeNewswire[Latest] Global Lenacapavir Injection Market Size/Share Worth USD 5.68 Billion by 2034 at a 5.1% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growt